AU2001256856A1 - Nutritional preparation comprising ribose and folic acid and medical use thereof - Google Patents

Nutritional preparation comprising ribose and folic acid and medical use thereof

Info

Publication number
AU2001256856A1
AU2001256856A1 AU2001256856A AU5685601A AU2001256856A1 AU 2001256856 A1 AU2001256856 A1 AU 2001256856A1 AU 2001256856 A AU2001256856 A AU 2001256856A AU 5685601 A AU5685601 A AU 5685601A AU 2001256856 A1 AU2001256856 A1 AU 2001256856A1
Authority
AU
Australia
Prior art keywords
ribose
folic acid
medical use
nutritional preparation
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001256856A
Inventor
Robert Johan Joseph Hageman
Rudolf Leonardus Lodewijk Smeets
George Verlaan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of AU2001256856A1 publication Critical patent/AU2001256856A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pediatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2001256856A 2000-05-08 2001-05-08 Nutritional preparation comprising ribose and folic acid and medical use thereof Abandoned AU2001256856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09566381 2000-05-08
US09/566,381 US6420342B1 (en) 2000-05-08 2000-05-08 Nutritional preparation comprising ribose and medical use thereof
PCT/NL2001/000349 WO2001085178A1 (en) 2000-05-08 2001-05-08 Nutritional preparation comprising ribose and folic acid and medical use thereof

Publications (1)

Publication Number Publication Date
AU2001256856A1 true AU2001256856A1 (en) 2001-11-20

Family

ID=24262649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001256856A Abandoned AU2001256856A1 (en) 2000-05-08 2001-05-08 Nutritional preparation comprising ribose and folic acid and medical use thereof

Country Status (7)

Country Link
US (2) US6420342B1 (en)
EP (1) EP1282426A1 (en)
JP (1) JP2003532679A (en)
CN (1) CN1304009C (en)
AU (1) AU2001256856A1 (en)
HK (1) HK1049625A1 (en)
WO (1) WO2001085178A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132582A (en) 1998-09-14 2000-10-17 The Perkin-Elmer Corporation Sample handling system for a multi-channel capillary electrophoresis device
ES2187115T3 (en) * 1999-01-20 2003-05-16 Nutricia Nv PREPARED FOR INFANTS.
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
WO2000067596A1 (en) * 1999-05-07 2000-11-16 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
US6576634B1 (en) * 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
ATE347896T1 (en) * 2000-07-28 2007-01-15 Bioenergy Inc COMPOSITIONS AND METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION
JP2004514685A (en) * 2000-11-29 2004-05-20 スミスクライン・ビーチャム・コーポレイション Dietary composition containing conjugated linoleic acid and calcium for improving health condition
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US6855727B2 (en) * 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20050025812A1 (en) * 2003-07-10 2005-02-03 Forest Carl A. Salad dressing with weight loss supplement
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US20020176881A1 (en) * 2001-01-26 2002-11-28 George Verlaan Rehydration composition
US7740878B2 (en) * 2001-10-22 2010-06-22 Danisco A/S Use of betaine to enhance exercise performance
CH696628A5 (en) * 2002-02-26 2007-08-31 Eprova Ag Use of folate suitable for the manufacture of a preparation for the prevention and treatment of inflammation and inflammation-associated diseases, in particular for influencing the
WO2003077899A1 (en) * 2002-03-16 2003-09-25 Seog-Nyeon Bae Anticancer composition
US20040147458A1 (en) * 2002-03-28 2004-07-29 Van Tassel Richard K Compositions to reduce exercise-induced swelling of joints
EP1575501A2 (en) * 2002-07-12 2005-09-21 University of Rochester Use of amino acids for treatment of various conditions
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7074418B2 (en) * 2002-11-18 2006-07-11 Changaris David G Conjugated fatty acid based emulsion and methods for preparing and using same
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) * 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
EP1625851A4 (en) * 2003-05-16 2007-12-26 Bbk Bio Corp Preparation for preventing contact of pathogenic matter with living organism
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
DE602004002596T2 (en) 2003-07-01 2007-08-23 Parker-Hannifin Corp., Cleveland FILTER ARRANGEMENT
WO2005006890A2 (en) * 2003-07-10 2005-01-27 Forest Carl A Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20050048136A1 (en) * 2003-08-27 2005-03-03 Choudhry Muhammad S. Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness
AU2004273759A1 (en) * 2003-09-19 2005-03-31 N.V. Nutricia Method and composition for preventing multiple organ dysfunction syndrome
WO2005030243A1 (en) * 2003-09-26 2005-04-07 Bristol Myers Squibb Company Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
NO320989B1 (en) * 2003-12-05 2006-02-20 Pigeon Vitality As Feed additive containing a carboxylic acid and / or its salt as a basic component of the additive.
US20090197818A1 (en) * 2004-01-14 2009-08-06 St Cyr John A Use Of Ribose for Recovery From Anaesthesia
US20070191287A1 (en) * 2004-03-18 2007-08-16 Michio Yamamura D-ribose for improving depression-like symptoms
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050238710A1 (en) * 2004-04-23 2005-10-27 Philip Connolly Vitamin replacement as a hangover ameliorative
JP2005336176A (en) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd Body fatigue restorer
EP1786436B1 (en) * 2004-04-29 2012-11-14 RiboCor, Inc. Method for improving ventilatory efficiency
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US20080306011A1 (en) * 2004-05-26 2008-12-11 National University Corporation Kagawa University Method of Controlling the Proliferation of Vascular Endothelial Cells and Inhibiting Lumen Formation
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
DE102004041270A1 (en) 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa A capillary action system containing application differential differentiation compositions and their use
JP2006069958A (en) * 2004-09-02 2006-03-16 Bio Igaku Kenkyusho Kk Age resistor
WO2006034586A1 (en) * 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
EP1645276A1 (en) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Treatment of neurodegenerative disorders
KR100653877B1 (en) 2004-12-23 2006-12-05 한서제약 주식회사 Composition for preventing or treating liver diseases comprising ?-lipoic acid
JPWO2007013556A1 (en) 2005-07-28 2009-02-12 株式会社カネカ Cancer prevention composition
KR101487848B1 (en) 2005-07-29 2015-02-03 티마 파운데이션 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
WO2007016955A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Alcohol metabolism moderating composition
DE602005012089D1 (en) 2005-08-04 2009-02-12 Extarma Ag Liquid composition containing arginine and alpha-lipoic acid to improve sexual function
CN100356876C (en) * 2005-09-30 2007-12-26 北京康比特威创体育新技术发展有限公司 Beverage for promoting sportive recovery from fatigue
WO2007059031A2 (en) * 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
CA2633292C (en) 2005-12-16 2015-04-28 N.V. Nutricia Use of soluble dietary fibres against muscle wasting
AU2006331950A1 (en) 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production
JP4610499B2 (en) * 2006-02-27 2011-01-12 ポーラ化成工業株式会社 Food composition
WO2007129618A1 (en) * 2006-05-08 2007-11-15 National University Corporation Kagawa University Inhibitor of neutrophil activation/migration factor and use thereof
ES2307402B1 (en) * 2006-10-30 2009-09-30 Archivel Farma, S.L. PROFILACTIC VACCINE AGAINST TUBERCULOSIS.
JPWO2008069276A1 (en) 2006-12-06 2010-03-25 株式会社カネカ Cancer therapeutic agent and carcinogenesis inhibitor
US8835396B2 (en) * 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
CN101588807B (en) * 2007-01-23 2012-07-04 生物能公司 Use of d-ribose to treat cardiac arrhythmias
US20080254049A1 (en) * 2007-04-10 2008-10-16 Iomedix Cold International Srl Composition for Treatment of Colds and Associated Symptoms
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
WO2009057994A1 (en) * 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
US20090186098A1 (en) * 2008-01-18 2009-07-23 Jose Briceno Sports drink composition
JP5383244B2 (en) * 2008-02-19 2014-01-08 株式会社アーネストメディスン Nutritional agent suitable for improving symptoms or nutritional status of cancer patients
JP5527986B2 (en) * 2008-02-19 2014-06-25 株式会社アーネストメディスン Pharmaceutical composition
CN101951930A (en) * 2008-02-19 2011-01-19 阿奈斯特药品株式会社 To useful oral of the recovery of body function or through the intestinal compositions
CN102387805A (en) * 2008-04-02 2012-03-21 生物能公司 Use of ribose in first response to acute myocardial infarction
US20090286750A1 (en) * 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
CA2735949C (en) * 2008-05-16 2016-04-19 Bioenergy, Inc. Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
CN102164892A (en) * 2008-07-28 2011-08-24 波利梅伊公司 Anti-malarial compounds
CN101331950B (en) * 2008-08-05 2012-09-05 北京康比特体育科技股份有限公司 Nutritional supplement for increasing sports break-out force
CN105232564A (en) * 2008-08-20 2016-01-13 生物能生命科学公司 Use of D-ribose for fatigued subjects
CN101675932B (en) * 2008-09-16 2012-02-22 中国科学院上海生命科学研究院 Composition for preventing and treating amyotrophic lateral sclerosis
RU2011115192A (en) * 2008-09-19 2012-10-27 Нестек С.А. (Ch) DIETOLOGICAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER THERAPY
WO2010071421A1 (en) 2008-12-17 2010-06-24 N.V. Nutricia Probiotics for the treatment and/or prevention of pulmonary hypertension
US20120178672A1 (en) * 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
JP2011098896A (en) * 2009-11-04 2011-05-19 Kirin Holdings Co Ltd Composition for reducing uric acid value
JP2011136907A (en) * 2009-12-25 2011-07-14 Kirin Holdings Co Ltd Endurance-enhancing agent
CA2787318A1 (en) * 2010-01-21 2011-07-28 Paul Bradley Addis Composition for perinatal and neonatal stroke
CN102711522B (en) 2010-01-29 2015-09-09 雅培制药有限公司 Comprise the nutrient solution of the aseptic packaging of HMB
EP2528459B1 (en) 2010-01-29 2014-06-11 Abbott Laboratories Nutritional emulsions comprising calcium hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (en) 2010-06-10 2016-03-21 亞培公司 Substantially clear nutritional liquids comprising calcium hmb and soluble protein
RU2448722C2 (en) * 2010-06-11 2012-04-27 Александр Николаевич Калиниченко Method for preventing and treating tuberculosis
IT1402330B1 (en) * 2010-09-03 2013-08-30 Poli DIETARY SUPPLEMENT
US9198881B2 (en) 2011-01-18 2015-12-01 Stephen T. Sinatra Equine nutritional supplement
JP5788715B2 (en) * 2011-05-31 2015-10-07 キリンホールディングス株式会社 Reducing agent for oxygen consumption and energy consumption
WO2013154733A1 (en) * 2012-04-09 2013-10-17 Hill James W Protein restriction for disease prevention and treatment
CN105611926A (en) * 2013-10-09 2016-05-25 味之素株式会社 Anti-fatigue composition
CN105592725A (en) * 2013-10-09 2016-05-18 味之素株式会社 Foodstuff containing histidine and application therefor
JP6771853B2 (en) * 2014-03-31 2020-10-21 小林製薬株式会社 Vitamin B6 containing composition
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
CN105476012B (en) * 2015-12-24 2019-04-05 中健医用食品有限公司 A kind of special medicine purposes formula food and preparation method thereof
EP3411041A1 (en) 2016-02-01 2018-12-12 RiboCor, Inc. Use of ribose for treatment of subjects having congestive heart failure
CN106109491A (en) * 2016-08-25 2016-11-16 吴文国 Alimentation composition and the application in preparation treatment aplastic anemia medicine
CN107198078A (en) * 2017-06-05 2017-09-26 天津市德恒科技有限公司 Stage of icterus small peptide growing nutrient element and technique manufacturing method
JP2020531006A (en) 2017-08-18 2020-11-05 カルウッド ニュートリショナルズ，エルエルーシー Compositions and methods for increasing muscle mass and strength, treating the skin, reducing damage and weakness from aging and exposure, and improving recovery from stress such as exercise and trauma.
WO2019217935A1 (en) * 2018-05-10 2019-11-14 Bioenergy Life Science, Inc. Methods and compositions for increasing nad level in mammals with d-ribose and vitamin b3
CN112203650A (en) * 2018-06-21 2021-01-08 雀巢产品有限公司 Nicotinamide Adenine Dinucleotide (NAD) is used+) Compositions and methods of precursors and at least one ketone or ketone precursor
CN110742266B (en) * 2019-11-11 2022-11-01 江南大学 Total nutrient formula food for assisting in regulating intestinal immunity function
EP3981407A1 (en) * 2020-10-07 2022-04-13 WÖRWAG Pharma GmbH & Co.KG Biofactors for the treatment and prophylaxis of dementia
CN115770255A (en) * 2021-09-07 2023-03-10 深圳奥萨医药有限公司 Composition for adjuvant treatment of cancerous fever
CN114868924A (en) * 2022-05-13 2022-08-09 武汉工程大学 Composition based on D-ribose and amino acid and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350160A (en) 1971-06-29 1974-04-18 Foremost Mckesson Pharmaceutical compositions
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
IT1247125B (en) 1991-03-01 1994-12-12 Depha Team Srl DIETETIC OR PHARMACEUTICAL COMPOSITIONS FOR THE RESTORATION OF THE CELL CONTENT OF NUCLEOTID ADENINS IN THE SKELETAL AND CARDIAC MUSCLE.
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
FI19992239A (en) 1999-10-18 2001-04-19 Jurilab Ltd Oy nutritional Supplement

Also Published As

Publication number Publication date
JP2003532679A (en) 2003-11-05
CN1304009C (en) 2007-03-14
CN1429113A (en) 2003-07-09
US20020183263A1 (en) 2002-12-05
WO2001085178A1 (en) 2001-11-15
EP1282426A1 (en) 2003-02-12
US6420342B1 (en) 2002-07-16
HK1049625A1 (en) 2003-05-23
US6548483B2 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
AU2001256856A1 (en) Nutritional preparation comprising ribose and folic acid and medical use thereof
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IL154031A0 (en) Substituted sulfonylaminomethylbenzoic acid derivatives and preparation
AU2001294876A1 (en) Direct growth of nanotubes, and their use in nanotweezers
PT1296974E (en) 2-cyanopyrrolidine derivatives and their use as medicaments
AU2001287898A1 (en) Pyrazolopyridines and pyrazolopyridazines as antidiabetics
GB2361703B (en) Folic acid and/or vitamin B12-lactoferrin complex
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002354476A1 (en) Pyrazolopyridine derivatives and medicinal use thereof
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU6038601A (en) Amino acid derivatives and their use as medicines
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2001286621A1 (en) Human transporter family members and uses thereof
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU2002338509B2 (en) Improvements in and relating to the administration of copper to an animal
AU2001274309A1 (en) Phosphoglycan messengers and their medical uses
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2001262928A1 (en) Pharmaceutical compositions and their use
AU2002252773A1 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
AU2001284462A1 (en) Drugs and health foods
AUPQ760400A0 (en) Herbical formulations and methods of use thereof